ArticleFrontiers in surgery2025
Analysis of the feasibility and health-economics value of simultaneous bilateral pulmonary surgery.
Article in Frontiers in surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and objective: The increased use of chest CT for clinical diagnosis and screening has improved the detection of early-stage lung cancer and the identification of bilateral lung lesions. Despite this, consensus on the feasibility of simultaneous vs. staged bilateral surgery for patients with bilateral lesions remains elusive, necessitating further investigation. This study assessed the safety, feasibility, and health-economics value of simultaneous bilateral pulmonary surgery by comparing perioperative clinical indicators and medical costs with those of unilateral surgery and simulated staged bilateral surgery. Methods: A retrospective analysis was conducted using clinical data from 78 patients who underwent simultaneous bilateral pulmonary surgery at the Lung Cancer Center of West China Hospital of Sichuan University by the same medical team from January 2016 to October 2024. An equal number of patients who underwent unilateral surgery during the same period served as controls. Perioperative indicators were compared between these groups, and medical expenses were assessed against those of a second control group undergoing simulated staged surgery. Results: All surgeries in both the simultaneous group and the control group were completed successfully, with patients discharged after recovery. The average surgical duration for the 78 patients in the simultaneous group was greater than that in the control group (195.8 ± 58.8 min vs. 136.83 ± 49.1 min; Conclusion: When indications are appropriately adhered to, simultaneous bilateral lung surgery for patients with bilateral pulmonary lesions is both safe and feasible; it reduces medical costs, increases diagnostic and treatment efficiency, conserves medical resources, and offers significant health-economics benefits.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.